SCYNEXIS (SCYX) vs Serina Therapeutics (SER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Serina Therapeutics (SER) over the past year, losing 32.1% versus a loss of 64.3%. Over five years, SCYX leads with a -90.5% price change compared with -93.9% for SER. Serina Therapeutics is the larger company by market cap ($51.1 million vs $42.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCYX | SER |
|---|---|---|
| Share price | $4.22 | $2.01 |
| Market cap | $41.99M | $51.05M |
| 1-day change | -11.72% | 0.00% |
| YTD return | -16.53% | +5.07% |
| 1-year return | -32.11% | -64.30% |
| 5-year return | -90.53% | -93.88% |
| EPS (TTM) | $-0.89 | $-1.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.12 | $5.71 |
| 52-week low | $3.53 | $1.22 |
| Distance from 52-week high | -53.73% | -64.80% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +760.90% | +372.64% |
| Average volume | 279.10K | 64.02K |
| Shares outstanding | 9.95M | 25.40M |
| Employees | 18 | 16 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed SER by 32.2 percentage points over the past year.
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Healthcare · Drug Manufacturers - Specialty & Generic · 18 employees
About Serina Therapeutics
SER stock →Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Healthcare · Biotechnology · 16 employees
SCYX vs SER FAQ
Which is bigger, SCYNEXIS or Serina Therapeutics?
Serina Therapeutics (SER) is larger, with a market capitalization of $51.05M compared with $41.99M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, SCYX or SER?
SCYX returned -32.11% over the past 12 months, compared with -64.30% for SER (price return, excluding dividends). Past performance does not predict future results.
Are SCYNEXIS and Serina Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for SCYNEXIS and Biotechnology for Serina Therapeutics.